Paper · 41820368
VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.
Bertlin JAC and 11 others. Nat Commun, 2026. Cited by 1 paper, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING. Papers, record 41820368. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41820368
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Von Hippel-Lindau Tumor Suppressor Protein | Major topic |
| Carcinoma, Renal Cell | Major topic |
| Kidney Neoplasms | Major topic |
| Membrane Proteins | Major topic |
| Core Binding Factor beta Subunit | Major topic |
| Synthetic Lethal Mutations | Major topic |
| Humans | |
| STING Protein | |
| Animals | |
| Cell Line, Tumor | |
| CRISPR-Cas Systems | |
| Signal Transduction | |
| Gene Expression Regulation, Neoplastic | |
| Interferon Type I | |
| Mice | |
| cGAS-STING Signaling Pathway |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Wellcome Trust | United Kingdom | PubMed | PubMed | ||
| R01 CA284591 | NCI NIH HHS | United States | R01CA284591 | PubMed | NIH RePORTER |
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Update of | 39,282,259 | VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING. | https://conductscience.org/library/papers/39282259 |
Source PubMed
References128
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27,595,393 | On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. | Nature | 2016 | https://conductscience.org/library/papers/27595393 | PubMed |
| 2 | 27,302,953 | Structural basis for concerted recruitment and activation of IRF-3 by innate immune adaptor proteins. | Proc Natl Acad Sci U S A | 2016 | https://conductscience.org/library/papers/27302953 | PubMed |
| 3 | 8,386,878 | Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. | Virology | 1993 | https://conductscience.org/library/papers/8386878 | PubMed |
| 4 | 24,487,277 | Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. | Nat Genet | 2014 | https://conductscience.org/library/papers/24487277 | PubMed |
| 5 | 34,070,756 | STING Agonists as Cancer Therapeutics. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34070756 | PubMed |
| 6 | 24,481,216 | E-CRISP: fast CRISPR target site identification. | Nat Methods | 2014 | https://conductscience.org/library/papers/24481216 | PubMed |
| 7 | 32,202,065 | Mitochondrial DNA in inflammation and immunity. | EMBO Rep | 2020 | https://conductscience.org/library/papers/32202065 | PubMed |
| 8 | 31,894,317 | Transcription factor RUNX2 regulates epithelial‑mesenchymal transition and progression in renal cell carcinomas. | Oncol Rep | 2020 | https://conductscience.org/library/papers/31894317 | PubMed |
| 9 | 28,926,338 | MELK is not necessary for the proliferation of basal-like breast cancer cells. | Elife | 2017 | https://conductscience.org/library/papers/28926338 | PubMed |
| 10 | 16,379,004 | Interferon regulatory factor 3 is necessary for induction of antiviral genes during human cytomegalovirus infection. | J Virol | 2006 | https://conductscience.org/library/papers/16379004 | PubMed |
1 to 10 of 128
See all 128 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,852,338 | SNU523 Inhibits Pancreatic Cancer through the Dual Suppression of STAT3 and MEK Signaling Pathways. | ACS Omega | 2026 | https://conductscience.org/library/papers/42852338 | PubMed |
| 42,593,521 | Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD). | Cancer Metastasis Rev | 2026 | https://conductscience.org/library/papers/42593521 | PubMed |
| 41,420,106 | Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities. | EMBO Mol Med | 2026 | https://conductscience.org/library/papers/41420106 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CBFB | 865 | PubTator's text mining | https://conductscience.org/library/genes/865 | NCBI Gene |
| STING1 | 340,061 | PubTator's text mining | https://conductscience.org/library/genes/340061 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41820368
GET https://conductscience.org/api/papers/v1/41820368/references?page=2